Question · asked by 1 review

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy: Serious adverse events

Population
people with advanced biliary tract carcinomas
Intervention
Gemcitabine plus oxaliplatin
Comparison
5‐fluorouracil plus cisplatin plus radiotherapy
Outcome
Serious adverse events

It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane Headline outcomes only
RR 1.5 [0.66, 3.39]1 study · 34 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas
2018 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.